Stockscreener 앱 받기
14.75
9.42%
1.27
시간 외 거래:
15.08
0.33
+2.24%
전일 마감가:
$13.48
열려 있는:
$13.53
하루 거래량:
2.51M
Relative Volume:
1.76
시가총액:
$1.27B
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-4.2121
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
+6.19%
1개월 성능:
+7.43%
6개월 성능:
+13.99%
1년 성능:
+35.94%
1일 변동 폭
$13.40
$14.76
1주일 범위
$12.37
$14.76
52주 변동 폭
$9.65
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.75 | 1.17B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EyePoint Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - Kalkine
Cormorant Asset Management (EYPT) reports 7,000,000 EyePoint shares in 13G/A - Stock Titan
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System - marketbeat.com
EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing - simplywall.st
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT) - marketbeat.com
EyePoint Pharmaceuticals, Inc. (EYPT) options chain - Yahoo Finance UK
Adage Capital discloses 4.79M-share EyePoint, Inc. (EYPT) position in Schedule 13G - Stock Titan
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - Kalkine
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $39 - moomoo.com
Eyepoint Pharma earnings missed by $0.15, revenue topped estimates - Investing.com Nigeria
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
HC Wainwright Issues Negative Outlook for EYPT Earnings - marketbeat.com
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharma nears key Phase III data for DU... - pluang.com
EyePoint: Phase 3 Design Creates A More Valuable Durability Story (NASDAQ:EYPT) - Seeking Alpha
EyePoint Is Maintained at Buy by Chardan Capital - Moomoo
EYPT Maintained by Chardan Capital -- Price Target Remains at $6 - GuruFocus
Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 218% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results - MarketBeat
EYPT Maintained by Cantor Fitzgerald -- Price Target Raised to $55 - GuruFocus
EyePoint, Inc. Stock 12‑Month Price Target Cut to $40.86, Implies 234% Upside - TradingView
EYPT Maintains by HC Wainwright & Co. -- Price Target Lowered to $27 - GuruFocus
HC Wainwright Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald - MarketBeat
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $55 - Moomoo
Is EyePoint Inc (EYPT) Worth the Price After Q2 Earnings Miss? G - GuruFocus
EyePoint, Inc. 2Q 2026: Revenue $507K, Net loss $(94.47M), EPS $(1.09) — 10-Q Summary - TradingView
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
EyePoint Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000 - marketscreener.com
EYPT Looks 1591.3% Overvalued on GF Value™ - GuruFocus
EyePoint: Q2 Earnings Snapshot - marketscreener.com
EyePoint Pharmaceuticals Q2 revenue drops on lower license income - TradingView
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Q2 revenue falls to $0.5 million as Phase 3 data nears - Quiver Quantitative
EYPT: Q2 2026 featured higher R&D costs and a $94.5M net loss as DURAVYU Phase 3 trials progressed - TradingView
EyePoint reports Q2 loss of $94.5M, cash and investments $180M; LUGANO topline due Aug 2026 - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, Vs. FactSet Est of $390,000 - Moomoo
EyePoint, Inc. (Nasdaq: EYPT) widens loss as DURAVYU Phase 3 trials near key data - Stock Titan
Eyepoint Pharma earnings on deck ahead of pivotal trial data - Investing.com
Eyepoint Pharma earnings on deck ahead of pivotal trial data By Investing.com - Investing.com South Africa
EYPT: DURAVYU advances as a potential first-in-class, long-acting TKI for major retinal diseases - TradingView
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.3%Here's Why - marketbeat.com
Janus Henderson Group PLC Grows Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT - marketbeat.com
Price to earnings forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Vanguard Capital Management (EYPT) discloses 4.22M-share, 5.03% holding in EyePoint - Stock Titan
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):